Fate Therapeutics (FATE) Non-Current Assets (2012 - 2026)

Fate Therapeutics' Non-Current Assets history runs 15 years deep, the most recent figure standing at $105.4 million for Q1 2026.

• Quarterly Non-Current Assets fell 29.95% year-over-year to $105.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $479.3 million (down 30.87% YoY) and the FY2025 annual result came in at $110.2 million, down 25.91% from the prior year.
• Non-Current Assets was $105.4 million for Q1 2026 at Fate Therapeutics, down from $110.2 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $259.3 million in Q1 2022 and bottomed at $105.4 million in Q1 2026.
• A 5-year average of $174.8 million and a median of $179.6 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2024 — Non-Current Assets increased 8.75% — and 2025, when it tumbled 33.71%.
• Fate Therapeutics' Non-Current Assets stood at $203.5 million in 2022, then fell by 14.16% to $174.7 million in 2023, then slipped by 14.82% to $148.8 million in 2024, then decreased by 25.91% to $110.2 million in 2025, then slipped by 4.39% to $105.4 million in 2026.
• Business Quant data shows FATE's Non-Current Assets at $105.4 million in Q1 2026, $110.2 million in Q4 2025, and $122.4 million in Q3 2025.